Bio-Rad Laboratories, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $651.0M | $592.1M | $693.2M | $653.0M | $651.6M | $585.4M | $667.5M | $649.7M |
| Cost of Revenue | $305.2M | $282.7M | $348.0M | $309.6M | $306.3M | $279.4M | $325.5M | $293.8M |
| Gross Profit | $345.8M | $309.4M | $345.2M | $343.4M | $345.3M | $306.0M | $342.0M | $355.9M |
| Gross Margin | 53.1% | 52.3% | 49.8% | 52.6% | 53.0% | 52.3% | 51.2% | 54.8% |
| Operating Expenses | ||||||||
| Research & Development | $61.2M | $62.9M | $70.3M | $71.3M | $60.5M | $73.5M | $79.6M | $91.0M |
| SG&A Expense | $212.0M | $212.4M | $221.0M | $206.8M | $207.7M | $208.8M | $204.0M | $200.4M |
| Operating Income | $72.6M | $34.1M | $-118.9M | $65.3M | $77.1M | $23.7M | $58.4M | $64.5M |
| Operating Margin | 11.2% | 5.8% | -17.2% | 10.0% | 11.8% | 4.0% | 8.7% | 9.9% |
| Interest Expense | $12.1M | $12.3M | $12.1M | $12.3M | $12.6M | $12.0M | $12.2M | $12.1M |
| Pretax Income | $542.1M | $-689.8M | $929.2M | $-431.1M | $414.0M | $83.4M | $-908.9M | $861.6M |
| Income Tax Expense | $170.7M | $-162.7M | $209.2M | $-89.2M | $96.2M | $19.4M | $-193.1M | $208.4M |
| Net Income | $371.4M | $-527.1M | $720.0M | $-341.9M | $317.8M | $64.0M | $-715.8M | $653.2M |
| Net Margin | 57.1% | -89.0% | 103.9% | -52.4% | 48.8% | 10.9% | -107.2% | 100.5% |
| EPS (Basic) | $13.89 | $-19.55 | $26.61 | $-12.70 | $11.67 | $2.29 | $-25.57 | $23.37 |
| EPS (Diluted) | $13.85 | $-19.55 | $26.59 | $-12.70 | $11.67 | $2.29 | $-25.57 | $23.34 |
| Shares Outstanding (Basic) | 26.7M | 27.0M | 27.3M | 26.9M | 27.2M | 27.9M | 28.2M | 27.9M |
| Shares Outstanding (Diluted) | 26.8M | 27.0M | 27.3M | 26.9M | 27.2M | 28.0M | 28.2M | 28.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |